Abstract
The last decade of research has witnessed a tremendous upsurge in our understanding of the intestinal microbiome and its role in a large range of human diseases, which has incited hopes for a rapid clinical utilization of the new insights for the development of microbiome-based therapies. Nonetheless, only a single microbiome-targeted therapy has so far found its way into clinical routine: fecal microbiota transplantation for patients suffering from recurrent Clostridium difficile infections. Herein, we discuss the current hopes, advances, challenges, and obstacles for translating basic microbiome research into therapeutic applications for a larger number of diseases and provide an outline of how such clinical applications might emerge.
Original language | English |
---|---|
Pages (from-to) | 1021-1027 |
Number of pages | 7 |
Journal | Journal of Molecular Medicine |
Volume | 95 |
Issue number | 10 |
DOIs | |
State | Published - 1 Oct 2017 |
All Science Journal Classification (ASJC) codes
- Drug Discovery
- Genetics(clinical)
- Molecular Medicine